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Table S1. Top10 predicted active ensembles structures of human mu opioid receptor 
(µ-OR) from the BiHelix procedure. Four different energies, charged total 
energy (CTotal), charged interhelical (CInterH), neutral total (NTotal) and 
neutral interhelical (NInterH) energy, associated with each 7-helix (H) bundles 
were evaluated and ranked. The structures were ordered by the average rank 
of these four energies (RankCNti). Chosen 3 conformers for SuperBiHelix 
sampling are all-zero structures modeled from active μ-OR, inactive δ-OR, and 
inactive  -OR (highlighted in gray). 
 
Rank 
CNti 
H1 H2 H3 H4 H5 H6 H7 Source CInterH CTotal NInterH NTotal 
1 0 0 0 0 0 0 0 active μ-OR -585.63 -412.49 -483.99 -493.34 
2 0 0 0 0 0 0 0 inactive δ-OR -568.50 -298.47 -498.05 -389.21 
3 0 0 0 0 0 0 0 inactive μ-OR -555.79 -243.89 -477.31 -346.49 
4 0 0 0 0 0 90 0 active μ-OR -547.59 -275.92 -445.12 -381.11 
5 0 0 0 0 30 0 0 inactive δ-OR -557.87 -212.57 -458.30 -321.67 
6 -30 0 0 0 0 0 0 active μ-OR -530.57 -278.27 -435.89 -375.60 
7 0 0 0 0 180 180 0 active μ-OR -533.37 -250.65 -433.39 -359.27 
8 0 0 0 0 180 0 0 inactive δ-OR -540.11 -213.09 -457.24 -323.18 
9 -90 0 0 0 0 0 0 active μ-OR -524.34 -302.76 -433.12 -409.93 
10 0 0 0 0 -60 0 0 active μ-OR -542.71 -323.47 -419.39 -377.76 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S2. Top25 predicted active ensembles structures of human mu opioid receptor 
(µ-OR) from the SuperBiHelix procedure. Four different energies, charged total 
energy (CTotal), charged interhelical (CInterH), neutral total (NTotal) and 
neutral interhelical (NInterH) energy, associated with each 7-helix (H) bundles 
were evaluated and ranked. The wild-type (WT) structures were ordered by the 
average rank of these four energies (RankCNti). Source (Soc) is from Bihelix 
(BH) rank in Table S13. 
H1 H2 H3 H4 H5 H6 H7 H1 H2 H3 H4 H5 H6 H7 H1 H2 H3 H4 H5 H6 H7 Soc WT 
0 0 0 0 0 0 0 0 0 0 -30 -30 -15 0 0 0 0 0 15 -15 0 3 1 
0 0 0 0 0 0 0 0 0 0 30 0 0 0 0 0 -15 -15 0 0 0 1 2 
0 0 0 0 0 0 0 0 0 0 -15 0 0 0 0 0 0 0 0 0 0 1 3 
0 0 0 0 0 0 0 0 0 0 -15 0 0 0 0 0 -15 0 0 0 0 1 4 
0 0 0 0 0 0 0 0 0 0 30 0 -15 0 0 0 -15 0 0 0 0 1 5 
0 0 0 0 0 0 0 0 0 0 30 -30 -15 0 0 0 0 0 15 -15 0 3 6 
0 0 0 0 0 0 0 0 0 0 0 -30 0 0 0 0 0 0 15 0 0 3 7 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 8 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 9 
0 0 0 0 0 0 0 0 0 0 -30 0 0 0 0 0 0 0 0 0 0 1 10 
0 0 0 0 0 0 0 0 0 0 -30 0 -15 -15 0 0 0 0 0 0 0 3 11 
0 0 0 0 0 0 0 0 0 0 30 0 0 0 0 0 -15 0 0 0 0 1 12 
0 0 0 0 0 0 0 0 0 0 15 0 0 0 0 0 -15 0 0 0 0 1 13 
0 0 0 0 0 -10 0 0 0 0 -30 -30 -15 15 0 0 0 0 15 -15 0 3 14 
0 0 0 0 -10 0 0 0 0 -15 -15 -30 15 0 0 0 0 0 0 0 0 3 15 
0 0 0 0 0 0 0 0 0 0 15 -30 0 0 0 0 0 0 15 0 0 3 16 
0 0 0 0 0 -10 0 0 0 0 30 -30 0 15 0 0 0 0 15 -15 0 3 17 
0 0 0 0 0 -10 0 0 0 0 15 -30 15 15 0 0 0 0 15 -15 0 3 18 
0 0 0 0 0 -10 0 0 0 0 0 -30 0 15 0 0 0 0 15 -15 0 3 19 
0 0 0 0 0 0 0 0 0 0 -15 -30 0 0 0 0 0 0 15 0 0 3 20 
0 0 0 0 0 0 0 0 0 0 -30 -30 0 0 0 0 0 0 15 0 0 3 21 
0 0 0 0 -10 0 0 0 0 -15 -30 -30 15 0 0 0 0 0 0 0 0 3 22 
0 0 0 0 0 -10 0 0 0 0 30 -30 -30 15 0 0 0 0 30 -15 0 3 23 
0 0 0 0 0 0 0 0 0 -15 -15 -15 15 0 0 0 0 0 -30 0 0 3 24 
0 0 0 0 0 0 0 0 0 0 -30 -30 0 0 0 0 0 0 30 0 0 3 25 
 
  
Table S3. H-bonding analysis of Top25 predicted active ensembles structures of 
human mu opioid receptor (µ-OR) from the SuperBiHelix procedure. The 
number of inter and total hydrogen bond (HB) and their energies were 
calculated. The number of active and inactive, and Class A contacts were also 
calculated.  
   
rank # inter HB # tot HB Inter HBE sum HBE # active # inactive # Class A Contacts 
1 23 46 -61.34 -146.30 0 5 38 
2 21 38 -61.86 -139.01 7 0 37 
3 14 33 -37.64 -120.62 7 0 39 
4 20 35 -53.19 -124.41 6 0 37 
5 20 35 -55.88 -136.91 7 0 38 
6 22 44 -57.70 -137.77 0 5 38 
7 19 34 -50.22 -91.58 0 6 39 
8 15 33 -34.62 -113.01 7 0 39 
9 15 33 -34.62 -113.01 7 0 39 
10 16 30 -40.56 -109.67 7 0 39 
11 18 30 -55.89 -114.36 0 6 40 
12 23 39 -59.36 -139.94 6 0 38 
13 24 39 -58.08 -138.54 6 0 37 
14 25 40 -62.43 -121.66 0 2 38 
15 26 40 -57.36 -117.40 0 4 38 
16 22 36 -54.67 -90.35 0 6 39 
17 23 38 -54.28 -111.90 0 3 38 
18 23 37 -61.14 -121.11 0 2 38 
19 21 37 -51.01 -109.14 0 3 38 
20 21 36 -46.88 -86.84 0 6 39 
21 20 35 -50.55 -90.49 0 6 39 
22 27 41 -56.59 -116.38 0 4 38 
23 21 35 -59.40 -111.74 1 3 39 
24 14 25 -42.46 -90.22 0 6 39 
25 19 37 -46.99 -103.72 0 7 39 
 
 
 
 
 
 
 
 
 
 
 
Table S4. Top10 predicted active ensembles structures of human kappa opioid 
receptor (κ-OR) from the BiHelix procedure. Four different energies, charged 
total energy (CTotal), charged interhelical (CInterH), neutral total (NTotal) and 
neutral interhelical (NInterH) energy, associated with each 7-helix (H) bundles 
were evaluated and ranked. The structures were ordered by the average rank 
of these four energies (RankCNti). Chosen 4 conformers for SuperBiHelix 
sampling are all-zero structures of inactive κ-OR, active µ-OR, partial active κ-
OR, and #13 (highlighted in gray). 
Rank CNti H1 H2 H3 H4 H5 H6 H7 Source CInterH CTotal NInterH NTotal 
1 0 0 0 0 0 0 0 inactive κ-OR -567.60 -286.29 -478.62 -417.01 
2 0 0 0 0 0 0 0 active μ-OR -565.28 -195.68 -461.16 -340.47 
3 0 0 0 0 30 0 0 inactive κ-OR -557.73 -170.69 -461.31 -328.68 
4 180 0 0 0 0 0 0 active μ-OR -567.76 -164.71 -453.27 -310.12 
5 0 0 0 0 -30 0 0 inactive κ-OR -553.67 -131.88 -469.10 -331.09 
6 0 0 0 0 0 0 0 partial active κ-OR -563.91 -124.13 -492.08 -313.34 
7 0 0 0 0 90 0 0 active μ-OR -530.24 -192.57 -449.57 -320.34 
8 0 0 0 0 0 0 0 inactive μ-OR -533.51 -155.51 -456.25 -296.89 
9 -
120 
0 0 0 0 0 0 active μ-OR -552.57 -160.87 -430.88 -299.79 
10 90 0 0 0 0 0 0 inactive κ-OR -522.19 -216.94 -428.90 -371.70 
11 -90 0 0 0 0 0 0 mOPRMAg -531.88 -144.47 -428.99 -301.31 
12 0 0 0 0 120 0 0 mOPRMAg -507.17 -162.73 -437.53 -303.06 
13 0 0 0 0 30 90 0 hOPRK -519.90 -87.35 -458.02 -312.23 
14 0 0 0 0 30 -30 0 hOPRK -534.26 -86.28 -446.01 -275.20 
15 0 0 0 -30 30 0 0 hOPRK -549.35 -120.83 -447.45 -243.95 
16 0 0 0 0 0 90 0 mOPRMAg -514.36 -126.47 -422.63 -312.89 
17 0 0 -30 0 0 0 0 hOPRK -506.77 -160.39 -424.22 -300.88 
18 0 0 0 0 -150 -90 0 mOPRMAg -522.99 -108.89 -433.28 -254.42 
19 0 0 0 30 0 0 0 hOPRK -508.45 -137.63 -416.63 -318.17 
20 0 0 0 0 90 90 0 mOPRMAg -536.38 -99.39 -438.67 -244.46 
 
 
  
Table S5. Top25 predicted active ensembles structures of human kappa opioid 
receptor (κ-OR) from the SuperBiHelix procedure. Four different energies, 
charged total energy (CTotal), charged interhelical (CInterH), neutral total 
(NTotal) and neutral interhelical (NInterH) energy, associated with each 7-helix 
(H) bundles were evaluated and ranked. The active wild-type (WT’) structures 
were ordered by the average rank of these four energies (RankCNti). Source 
(Soc) is from Bihelix (BH) rank in Table S4 
. 
H1 H2 H3 H4 H5 H6 H7 H1 H2 H3 H4 H5 H6 H7 H1 H2 H3 H4 H5 H6 H7 Soc WT’ 
0 0 0 0 0 0 0 0 0 0 -15 0 15 0 0 0 0 -15 0 0 0 2 1 
0 0 0 0 0 0 0 0 0 0 0 0 15 0 0 0 0 0 0 0 0 2 2 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 -15 0 0 0 2 3 
0 0 0 0 0 0 0 0 0 0 0 0 30 0 0 0 0 -15 0 0 0 2 4 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 -15 0 0 0 0 2 5 
0 0 0 0 0 0 0 0 0 0 -15 0 30 0 0 0 0 -15 0 0 0 2 6 
0 0 0 0 0 0 0 0 0 0 0 -15 0 0 0 0 0 -15 0 0 0 2 7 
0 0 0 0 10 0 0 0 0 0 30 -15 -15 0 0 0 -15 -15 15 0 0 2 8 
0 0 0 0 0 0 0 0 0 0 30 0 15 0 0 0 0 0 0 0 0 2 9 
0 0 0 0 0 0 0 0 0 0 30 0 0 0 0 0 -15 -15 0 0 0 2 10 
0 0 0 0 0 0 0 0 0 0 -30 0 0 0 0 0 -15 0 0 0 0 2 11 
0 0 0 0 0 0 0 0 0 0 30 -15 15 0 0 0 0 0 0 0 0 2 12 
0 0 0 0 0 0 0 0 0 0 -15 0 0 0 0 0 0 -15 0 0 0 2 13 
0 0 0 0 0 0 0 0 0 0 0 -15 15 0 0 0 0 -15 0 0 0 2 14 
0 0 0 0 0 0 0 0 0 0 -15 0 15 0 0 0 0 0 0 0 0 2 15 
0 0 0 0 0 0 0 0 0 0 15 0 0 0 0 0 -15 0 0 0 0 2 16 
0 0 0 0 0 0 0 0 0 0 30 -15 0 0 0 0 0 0 0 0 0 2 17 
0 0 0 0 0 -10 0 0 0 0 0 0 15 30 0 0 0 0 0 -15 0 13 18 
0 0 0 0 10 -10 0 0 0 0 15 0 -30 30 0 0 -15 0 -15 -30 0 13 19 
0 0 0 0 0 0 0 0 0 0 30 0 0 0 0 0 -15 0 0 0 0 2 20 
0 0 0 0 0 0 0 0 0 0 15 0 30 0 0 0 0 0 0 0 0 2 21 
0 0 0 0 10 -10 0 0 0 0 15 0 -15 30 0 0 -15 0 -15 -30 0 13 22 
0 0 0 0 0 0 0 0 0 0 30 0 0 0 0 0 0 0 0 0 0 2 23 
0 0 0 0 0 -10 0 0 0 0 -15 0 15 30 0 0 0 0 0 -15 0 13 24 
0 0 0 0 0 0 0 0 0 0 -15 0 0 0 0 0 -15 0 0 0 0 2 25 
 
 
 
 
 
 
 
 
 
 
Figure S1. The dose-response activation of human mu opioid receptor by compound 
4. The data was normalized compare to DAMGO. 
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Figure S2. (Left) Binding site of Compound 13 at µ-OR and (Right) 2D ligand 
interaction diagram. The H-bond is represented by the arrows between the donor and 
the acceptor. Residues within 4 Å of ligand are shown on the 2D ligand interaction 
diagram displayed on the right. For clarity, only polar hydrogen atoms are shown. 
  
Figure S3. Structure of 56 groups at R2 for R-group screening based on ortho Cl 
substituent at R1 of compound 13. 
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1. Computational Methods  
1.1 The DarwinDock Method for Predicting Ligand-Protein Structures 
To predict the optimum ligand binding site to each of the 24 protein conformations 
from the GEnSeMBLE procedure, we used the DarwinDock method, which has 
previously been used to predict ligand-protein structures for many GPCRs.[1] 
 
1.1.1 Selecting Ligand Conformations  
Starting from the X-ray structure of each ligand, we sampled the torsion angles of 
all rotatable bonds to generate multiple conformations for each ligand. These were 
minimized using Maestro with 10 to 20 ligand conformations selected by energy and 
diversity. The charges on the ligands were chosen to be the Mulliken charges from 
density functional theory (B3LYP using the 6-311G** basis set).  
 
1.1.2 Scanning the Receptor for Potential Binding Regions  
For each of the 24 protein conformations, the whole protein was alanized 
(replacing the 6 hydrophobic residues, I, L, V, F, Y, and W with A). Then for each of 
the 10-20 ligand conformations, we scanned for potential binding regions with no 
assumption about the binding site. The entire molecular surface was mapped with 
spheres representing the empty volume of the protein. These spheres were partitioned 
using the BoxSpheres.pl script to generate 10 Å cubic boxes for each protein 
conformation. This led to a minimum of 73 boxes for WT13 and a maximum of 83 for 
WT24 (the WT number from the SuperBiHelix analysis is in Table S1). We then used 
DOCK4.070 to generate 1000 poses for each of these 73-83 regions and selected the 
most promising three or four putative binding regions for docking.  
 
2. Generating the active ensembles for κ-OR  
To understand the activation of µ-OR by compound 4, we used the GEnSeMBLE 
complete sampling method to generate the ensemble of 24 structures for human µ-OR 
and κ-OR. [2] As TM templates, we used crystal structures of µ -OR activated structures: 
BU72 agonist bound mouse µ -OR (PDB ID code 5C1M)[3] κ -OR inactivated structures: 
antagonist JDTic bound to human κ -OR (PDB ID code 4DJH),37 antagonist morphinan 
mouse bonded to µ-OR (PDB ID code 4DKL),[4] antagonist Naltrindole bonded to 
human δ-OR (PDB ID code 4N6H),[5] peptide mimetic antagonist compound-24 (C-24) 
bonded human nociceptin receptor (PDB ID code 4EA3),[6] and one partial agonist 
(EKC) bonded to κ-OR.51 For each of the 6 templates we carried out the BiHelix 
analysis for both human µ−OR and κ-OR, examining 6*127 = 220 million packings. 
Then, we analyzed the predicted packing using the GRoSS active hotspots and the 
GRoSS inactive hotspots. 
 
2.1 κ-OR 
2.1a BiHelix. As shown in Table S10, 15 of the best 25 are from inactive κ-OR and µ-
OR and 10 are from the active µ-OR crystal structure. Thus, 15 show inactive hot spot 
contacts. To optimize the TM helix tilts along with rotations we carried out SuperBihelix 
complete sampling for 4 templates from BiHelix selected based on energy and 
diversity. For SuperBihelix optimization of tilts and rotations, we selected two X-ray 
templates (inactive and active µ-OR), one predicted structure (κ-OR bound with partial 
agonist), and #17 for diversity in Table S10. In the Bihelix predictions, the X-ray 
template of inactive κ -OR has the most inactive hotspots (7) and the most Class A 
contacts (40). For the active template, we selected the X-ray template of active μ-OR. 
 
2.1b SuperBiHelix for best active 
The SuperBihelix considered tilt angles of θ=0,±10°, azimuthal angles of φ=0, ±15°, 
±30°, and rotation angles of η=0, ±15°, ±30°, for a total of 13 trillion that was reduced 
to the Top25 based on the packing of the best 7-helix bundles, all from inactive κ-OR. 
Then we excluded the κ-OR template, and rescored to find that the majority (21 of 25) 
are from µ-OR active template (Table S5). All Top25 and 19 models have salt-bridges 
between R3.50-D7.57 and between R5.69-D6.37 which are unique for active 
ensembles, respectively. But we do not observe any TM 3-5-6 H-bonding networks in 
blue, which are unique for inactive ensembles (Table S1) except for two cases from 
inactive κ-OR template (#13). Out of the Top25, 20 are from active μ-OR template and 
4 are from inactive κ-OR template (#13). Thus, most structures in the ensemble are 
expected to be active. 
2.1c SuperBiHelix for best inactive 
Table S4 shows the top25 inactive structures from inactive κ-OR. All show 6 to 7 
inactive hot spot interactions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. Spectroscopy of final compounds 
1-(5-(3-chlorophenyl)-7,8-dimethoxy-3-(3-methoxybenzyl)-3H-pyrazolo[3,4-
c]isoquinolin-1-yl)-N,N-dimethylmethanamine (15)  
 Proton NMR of compound 15 
 
 Carbon NMR of compound 15 
 
 
(5-(3-chlorophenyl)-7,8-dimethoxy-3-(naphthalen-2-ylmethyl)-3H-pyrazolo[3,4-
c]isoquinolin-1-yl)methanamine (16) 
 Proton NMR of compound 16 
 
 Carbon NMR of compound 16 
 
 
 
1-(5-(3-chlorophenyl)-7,8-dimethoxy-3-(4-(methylsulfonyl)benzyl)-3H-pyrazolo[3,4-
c]isoquinolin-1-yl)-N,N-dimethylmethanamine (19)  
 Proton NMR of compound 19 
 
 
 Carbon NMR of compound 19 
 
 
1-(5-(3-chlorophenyl)-7,8-dimethoxy-3-(naphthalen-2-ylmethyl)-3H-pyrazolo[3,4-
c]isoquinolin-1-yl)-N,N-dimethylmethanamine (20)  
 Proton NMR of compound 20 
 
 
 Carbon NMR of compound 20 
 
 
1-(5-(4-chlorophenyl)-7,8-dimethoxy-3-(naphthalen-2-ylmethyl)-3H-pyrazolo[3,4-
c]isoquinolin-1-yl)methanamine (22)  
 Proton NMR of compound 22 
 
 
 Carbon NMR of compound 22 
 
 
1-(5-(3-chlorophenyl)-7,8-dimethoxy-3-(4-methoxyphenethyl)-3H-pyrazolo[3,4-
c]isoquinolin-1-yl)-N,N-dimethylmethanamine (25)  
 Proton NMR of compound 25 
 
 
 Carbon NMR of compound 25 
 
 
1-(5-(4-chlorophenyl)-3-isobutyl-7,8-dimethoxy-3H-pyrazolo[3,4-c]isoquinolin-1-yl)-
N,N-dimethylmethanamine (26) 
 Proton NMR of compound 26 
 
 
 Carbon NMR of compound 26 
 
 
1-(5-(2-chlorophenyl)-7,8-dimethoxy-3-(4-methoxyphenethyl)-3H-pyrazolo[3,4-
c]isoquinolin-1-yl)-N,N-dimethylmethanamine (27) 
 Proton NMR of compound 27 
 
 Carbon NMR of compound 27 
 
 
 
3-(5-(3-chlorophenyl)-1-((dimethylamino)methyl)-7,8-dimethoxy-3H-pyrazolo[3,4-
c]isoquinolin-3-yl)propanenitrile (29) 
 Proton NMR of compound 29 
 
 Carbon NMR of compound 29 
 
 
 
1-(5-(3-chlorophenyl)-3-isobutyl-7,8-dimethoxy-3H-pyrazolo[3,4-c]isoquinolin-1-yl)-
N,N-dimethylmethanamine (30) 
 Proton NMR of compound 30 
 
 
 Carbon NMR of compound 30 
 
 
1-(5-(3-chlorophenyl)-7,8-dimethoxy-3-(2-(1-methylpyrrolidin-2-yl)ethyl)-3H-
pyrazolo[3,4-c]isoquinolin-1-yl)-N,N-dimethylmethanamine (31) 
 Proton NMR of compound 31 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1-(5-(4-chlorophenyl)-3-isobutyl-7,8-dimethoxy-3H-pyrazolo[3,4-c]isoquinolin-1-yl)-
N,N-dimethylmethanamine (33) 
 Proton NMR of compound 33 
 
 Carbon NMR of compound 33 
 
 
 
4. Spectroscopy of intermediate compounds 
4-(3,4-dimethoxyphenyl)-3-(methoxymethyl)-1H-pyrazol-5-amine (6) 
 Proton NMR of compound 6 
 
 
 
5-(3-chlorophenyl)-7,8-dimethoxy-1-(methoxymethyl)-3H-pyrazolo[3,4-c]isoquinoline 
(7a) 
 Proton NMR of compound 7a 
 
 
 
5-(4-chlorophenyl)-7,8-dimethoxy-1-(methoxymethyl)-3H-pyrazolo[3,4-c]isoquinoline 
(7b) 
 Proton NMR of compound 7b 
 
 
 
5-(2-chlorophenyl)-7,8-dimethoxy-1-(methoxymethyl)-3H-pyrazolo[3,4-c]isoquinoline 
(7c) 
 Proton NMR of compound 7c 
 
 
 
(5-(3-chlorophenyl)-7,8-dimethoxy-3H-pyrazolo[3,4-c]isoquinolin-1-yl)methanol (8a) 
 Proton NMR of compound 8a 
 
 
(5-(4-chlorophenyl)-7,8-dimethoxy-3H-pyrazolo[3,4-c]isoquinolin-1-yl)methanol (8c) 
 
 Proton NMR of compound 8b 
 
(5-(2-chlorophenyl)-7,8-dimethoxy-3H-pyrazolo[3,4-c]isoquinolin-1-yl)methanol (8c) 
 Proton NMR of compound 8c 
 
(5-(3-chlorophenyl)-7,8-dimethoxy-3H-pyrazolo[3,4-c]isoquinolin-1-yl)methanamine 
(9a) 
 Proton NMR of compound 9a 
 
 
(5-(4-chlorophenyl)-7,8-dimethoxy-3H-pyrazolo[3,4-c]isoquinolin-1-yl)methanamine 
(9b) 
 Proton NMR of compound 9b 
 
(5-(2-chlorophenyl)-7,8-dimethoxy-3H-pyrazolo[3,4-c]isoquinolin-1-yl)methanamine 
(9c) 
 Proton NMR of compound 9c 
 
 
tert-butyl ((5-(3-chlorophenyl)-7,8-dimethoxy-3H-pyrazolo[3,4-c]isoquinolin-1-
yl)methyl)carbamate (10a) 
 Proton NMR of compound 10a 
 
tert-butyl ((5-(4-chlorophenyl)-7,8-dimethoxy-3H-pyrazolo[3,4-c]isoquinolin-1-
yl)methyl)carbamate (10b) 
 Proton NMR of compound 10b 
 
tert-butyl ((5-(2-chlorophenyl)-7,8-dimethoxy-3H-pyrazolo[3,4-c]isoquinolin-1-
yl)methyl)carbamate (10c) 
 Proton NMR of compound 10c 
 
tert-butyl ((5-(3-chlorophenyl)-7,8-dimethoxy-3-(naphthalen-2-ylmethyl)-3H-
pyrazolo[3,4-c]isoquinolin-1-yl)methyl)carbamate (11d) 
 Proton NMR of compound 11d 
 
Tert-butyl ((5-(4-chlorophenyl)-7,8-dimethoxy-3-(naphthalen-2-ylmethyl)-3H-
pyrazolo[3,4-c]isoquinolin-1-yl)methyl)carbamate (11e) 
 Proton NMR of compound 11e 
 
1-(5-(3-chlorophenyl)-7,8-dimethoxy-3H-pyrazolo[3,4-c]isoquinolin-1-yl)-N,N-
dimethylmethanamine (12a) 
 Proton NMR of compound 12a 
 
1-(5-(4-chlorophenyl)-7,8-dimethoxy-3H-pyrazolo[3,4-c]isoquinolin-1-yl)-N,N-
dimethylmethanamine (12b) 
 Proton NMR of compound 12b 
 
1-(5-(2-chlorophenyl)-7,8-dimethoxy-3H-pyrazolo[3,4-c]isoquinolin-1-yl)-N,N-
dimethylmethanamine (12c) 
 Proton NMR of compound 12c 
 
5. Selectivity of compound 15 and 19 
 
5.1 % Activation of compound 15 and 19 against Human Kappa Opioid Receptor 
 
Figure S4. % Activation of human κ-OR using FLIPR calcium efflux assay. 10 µM of compound 15 and 
19 were treated. Positive control Dynorphin (370 nM) was used to compare the data.  
 
 
 
 
5.2 % Activation of compound 15 and 19 against Human Delta Opioid Receptor 
We used Eurofins (Eurofins Scientific, Luxembourg) GPCR service to confirm the delta 
opioid agonism of compound 15 and 19. 
 
Figure S5. % Activation of human δ-OR using fluorimetry calcium efflux assay. 10 µM of compound 15 
and 19 were treated. Positive control DPDPE (1 µM) was used to compare the data.  
 
 
 
 
 
 
 
 
 
 
 
6. Synthesis of compound 4 
Among the suggested 6 compounds, we were able to synthesize 4 successfully 
(Scheme S1). The commercially available 3,4-dimethoxy benzyl cyanide was reacted 
with ethyl methoxyacetate for the introduction of methoxy acetyl moiety at the benzyl 
position to afford compound 5. Cyclization using hydrazine hydrate led to amino-
methoxy-pyrazole compound 6, which was subsequently reacted with aluminum 
trichloride under an argon atmosphere to yield mixtures of compound 34 and its isomer 
product, 5-(5-amino-3-((dibenzylamino)methyl)-1H-pyrazol-4-yl)-2-methoxyphenol. 
The cyclization of this mixture under microwave conditions with 4-chlorobenzaldehyde 
afforded compound 35. In this step, only compound 34 was cyclized because of the 
position of the methoxy electron donating group. After selective O-demethylation using 
boron tribromide (36), the benzyl alcohol moieties were transformed to corresponding 
chlorides followed by primary amines through reactions using thionyl chloride and 2M 
ammonia solution in THF, respectively to provide compound 37. Compound 38 was 
prepared by protection of the amine with di-tert-butyl-dicarbonate. The phenolic moiety 
was protected with THP group (39) and then, N-alkylation of pyrazole moiety provided 
compound (40). The final product compound 4 was obtained by deprotection of the 
Boc & THP groups in strong acidic condition using trifluoroacetic acid. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme S1. Synthesis of compound 4. (a) potassium tert-butoxide, THF, RT, 2 h, 55%; (b) 
Hydrazine hydrate, AcOH, MeOH, reflux, 4 h, 60%; (c) AlCl3, DCM, 2 h, 67%; (d) 4-chloro 
benzaldehyde, TFA, Microwave irradiation, 140°C, 2 h, 44%; (e) BBr3, DCM, 0°C, 4 h, 45%; 
(f) thionyl chloride, reflux, 2 h, then 2M ammonia solution in THF solution, THF 65%; (g) di-
tert-butyl dicarbonate, TEA, DCM, RT, 1 h 71%; (h) 3,4-dihydro-2H-pyran, MsOH, DCM, 
RT, 1 h, 85%; (i) Halides, NaH, DMF, RT, 72%; (j) TFA, DCM, 0°C, 2 h, then TFA, MeOH, 
0°C 62%. 
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1-(aminomethyl)-5-(4-chlorophenyl)-3-(4-hydroxybenzyl)-8-methoxy-3H-
pyrazolo[3,4-c]isoquinolin-7-ol (4) 
N
N
N
O
HO
Cl
H2N
OH
 
A solution of compound 40 (15 mg, 0.023 mmols) in dichloromethane (2 ml) and 
methanol (2 ml) were cooled to 0°C, and trifluoro acetic acid (2 ml) was slowly 
added. Upon completion of reaction, the mixture was concentrated under reduced 
pressure. The residue was purified by silica gel column chromatography with MeOH: 
ammonia saturated CHCl3 (5%) to afford 4 as a yellow liquid. 
 
1H NMR (400 MHz, DMSO-d6) δ 9.03 (s, 1 H), 7.66 – 7.33 (m, 2 H) ,7.55 – 7.62 (m, 2 
H), 7.31 (s, 1 H), 6.75 (d, J=8.24 Hz, 2 H), 6.55 (d, J=8.24 Hz, 2 H), 4.65 (s, 2 H), 
3.91 (s, 2 H), 3.72 (s, 3 H). 
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